Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV … – News-Medical.net

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV
News-Medical.net
Advaxis, Inc., (OTCBB: ADXS) ("Advaxis" or the "Company"), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients
Advaxis and FusionVax Sign a Memorandum of Understanding for the License Business Wire (press release)

all 3 news articles »

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *